Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
May 15 2024 - 8:30AM
IMUNON, Inc.
(NASDAQ: IMNN), a clinical-stage
drug-development company focused on developing non-viral
DNA-mediated immunotherapy and next-generation vaccines, announces
that an abstract describing a Phase 2 study with IMNN-001 plus
bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced
epithelial ovarian cancer patients has been accepted for
presentation at the American Society of Clinical Oncology (ASCO)
annual meeting, to be held in Chicago from May 31st to June
4th.
The abstract, titled “A phase II study
evaluating the effect of IMNN-001 on second-look laparoscopy when
administered in combination with bevacizumab and neoadjuvant
chemotherapy in patients newly diagnosed with advanced epithelial
ovarian cancer,” will be presented on June 3rd at the Gynecologic
Cancer session between 9:00 a.m. and 12:00 p.m. CT by lead
investigator Amir A Jazaeri, M.D., Professor of Gynecological
Oncology & Reproductive Medicine at The University of Texas MD
Anderson Cancer Center. The study is actively recruiting patients
in the U.S.
Abstract
#: TPS5633Poster Board
#: 498aSession Title: Gynecologic
CancerLocation: Hall A
“This study, substantially funded by Break
Through Cancer, and with MD Anderson as the leading clinical site,
is a pivotal part of IMUNON’s IL-12 gene therapy development for
women with ovarian cancer. The combination with bevacizumab makes a
lot of sense as we have observed synergies in pre-clinical
experiments. We hope to complete enrollment of this study quickly
to answer this important clinical question,” said Dr. Sebastien
Hazard, IMUNON’ chief medical officer.
About IMUNON
IMUNON is a clinical-stage biotechnology company
focused on advancing a portfolio of innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases,
constituting a differentiating approach from conventional
therapies. IMUNON is developing its non-viral DNA technology across
its modalities. The first modality, TheraPlas®, is developed for
the coding of proteins and cytokines in the treatment of solid
tumors where an immunological approach is deemed promising. The
second modality, PlaCCine®, is developed for the coding of viral
antigens that can elicit a strong immunological response. This
technology may represent a promising platform for the development
of vaccines in infectious diseases.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
entering a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to
advance the technological frontier of plasmid DNA to better serve
patients with difficult-to-treat conditions. For more information
on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s filings with the
Securities and Exchange Commission. IMUNON assumes no obligation to
update or supplement forward-looking statements that become untrue
because of subsequent events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From May 2024 to Jun 2024
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From Jun 2023 to Jun 2024